Daclatasvir is a direct-acting antiviral agent and a potent inhibitor of the non-structural protein 5A (NS5A) of the hepatitis C virus. It is indicated for use in combination therapy to treat chronic hepatitis… Read more



![Chemical structure of 1,1'-((2S,2'S)-([1,1'-biphenyl]-4,4'-diylbis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(ethan-1-one)](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1447744-93-5-11-2S2S-11-biphenyl-44-diylbis1H-imidazole-52-diylbispyrrolidine-21-diylbisethan-1-one.png&w=3840&q=75)
![Chemical structure of 1,1'-([1,1'-biphenyl]-4,4'-diyl)bis(2-bromoethan-1-one)](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F4072-67-7-11-11-biphenyl-44-diylbis2-bromoethan-1-one.png&w=3840&q=75)
![Chemical structure of 1,1'-([1,1'-biphenyl]-4,4'-diyl)bis(2-chloroethan-1-one)](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F24860-53-5-11-11-biphenyl-44-diylbis2-chloroethan-1-one.png&w=3840&q=75)
![Chemical structure of 2,2'-([1,1'-Biphenyl]-2,4'-diyl)bis(2-bromoacetaldehyde)](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F22-11-Biphenyl-24-diylbis2-bromoacetaldehyde.png&w=3840&q=75)
![Chemical structure of 2,2-Dibromo-1-(4'-(2-bromoacetyl)-[1,1'-biphenyl]-4-yl)ethan-1-one](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2840793-71-5-22-Dibromo-1-4-2-bromoacetyl-11-biphenyl-4-ylethan-1-one.png&w=3840&q=75)
![Chemical structure of 2-((S)-Pyrrolidin-2-yl)-5-(4'-(2-((S)-pyrrolidin-2-yl)-1H-imidazol-5-yl)-[1,1'-biphenyl]-4-yl)oxazole](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2-S-Pyrrolidin-2-yl-5-4-2-S-pyrrolidin-2-yl-1H-imidazol-5-yl-11-biphenyl-4-yloxazole.png&w=3840&q=75)







































Daclatasvir is a direct-acting antiviral agent and a potent inhibitor of the non-structural protein 5A (NS5A) of the hepatitis C virus. It is indicated for use in combination therapy to treat chronic hepatitis C genotype 1, 3, or 4 infections. Laboratories utilize high-quality reference standards of Daclatasvir and its related compounds, including impurities, metabolites, and stable isotope-labelled versions, for critical analytical procedures. These materials are essential for accurate impurity profiling and method validation, ensuring that pharmaceutical preparations comply with stringent regulatory and pharmacopoeial standards. Stable isotope-labelled compounds are particularly valuable for precise quantification during quality control assessments. By providing reliable reference materials for structurally related analogs and degradation products, these compounds support the ongoing evaluation of drug potency, safety, and long-term stability throughout the pharmaceutical lifecycle, ensuring consistent performance in high-performance liquid chromatography and other routine analytical applications.